CNBX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 21:56):

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer...

Stats
Dagens volum	139 615
Gjennomsnittsvolum	232 904
Markedsverdi	354 670
EPS	$0 ( 2024-04-14 )
Neste inntjeningsdato	( $0 ) 2024-07-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2014-07-25	Cannabics Inc.	Buy	18 239 594	COMMON STOCK
2014-06-23	Cannabics Inc.	Buy	14 525 000	Common Stock
2014-05-08	Cannabics Inc.	Buy	20 500 000	Common Stock
2014-05-08	Mills Thomas E	Sell	20 500 000	common stock
2014-04-25	Mills Thomas E	Buy	20 500 000	common stock

INSIDER POWER
0.00
Last 15 transactions
Buy: 135 764 594 \| Sell: 73 500 000

Cannabics Pharmaceuticals Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cannabics Pharmaceuticals Økonomi

Annual	2023
Omsetning:	$410 165
Bruttogevinst:	$248 104 (60.49 %)
EPS:	$-0.420

FY	2023
Omsetning:	$410 165
Bruttogevinst:	$248 104 (60.49 %)
EPS:	$-0.420

FY	2022
Omsetning:	$29 958.00
Bruttogevinst:	$-168 569 (-562.68 %)
EPS:	$-3.08

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0200

Financial Reports:

No articles found.

Cannabics Pharmaceuticals

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.